Quercetin and EGCG show promise as complementary cancer therapies by inhibiting EGFR signaling and modulating related pathways, which enhance the effectiveness of conventional EGFR‐targeting treatments like tyrosine kinase inhibitors and cetuximab. Here, EGFR is linked to cancer.